JP Morgan Initiates Idera Pharmaceuticals With Overweight

JP Morgan initiated coverage on Idera Pharmaceuticals Inc IDRA with a Overweight rating. Idera Pharmaceuticals shares have gained 17.05 percent over the past 52 weeks, while the S&P 500 index has surged 8.07 percent in the same period. Idera Pharmaceuticals' shares rose 1.68 percent to $3.63 in pre-market trading.